{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:19Z","timestamp":1791903319592,"version":"4.3.4"},"reference-count":17,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>BMT CTN 1506 (MORPHO) was a phase 3 study of post\u2013hematopoietic cell transplantation (HCT) maintenance with gilteritinib vs placebo for patients with FLT3-ITD\u2013mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America but no benefit for those in Europe or Asia. We conducted a post hoc analysis of the data focusing on the time from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants who underwent transplantation &amp;lt;120 days from AML diagnosis and\/or those treated with FLT3 inhibition before HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = .001) in participants who underwent transplantation within 120 days from diagnosis and in those treated with an FLT3 inhibitor before HCT and underwent transplantation within 120 days (P = .008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, because participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to affect MRD levels immediately before HCT, and geographic differences in these 2 practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment before HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020327","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:24:07Z","timestamp":1785457447000},"page":"6754-6763","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Regional practice differences significantly affect the benefit of post-HCT gilteritinib in\n                    <i>FLT3-ITD<\/i>\n                    AML"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"first","affiliation":[{"name":"1Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research and Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Logan","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research and Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[{"name":"3Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"4Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-1861","authenticated-orcid":false,"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"6Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"8Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"9Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1976","authenticated-orcid":false,"given":"Masumi Ueda","family":"Oshima","sequence":"additional","affiliation":[{"name":"10Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"13Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"14Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"15Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"16Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"17Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"18Department of Medicine\/Hematology and Oncology, University of Muenster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"19Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-2864","authenticated-orcid":false,"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[{"name":"20Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Thomson","sequence":"additional","affiliation":[{"name":"21University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chen","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Hasabou","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-1661","authenticated-orcid":false,"given":"Jason","family":"Hill","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Gill","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishita","family":"Nuthethi","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"King","sequence":"additional","affiliation":[{"name":"23The Emmes Company, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mendizabal","sequence":"additional","affiliation":[{"name":"23The Emmes Company, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-759X","authenticated-orcid":false,"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[{"name":"24National Marrow Donor Program, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research and Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"25Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"15","key":"2026101310433192200_bib1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026101310433192200_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026101310433192200_bib3","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.34843","article-title":"Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: a European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study","volume":"129","author":"Al Hamed","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"2026101310433192200_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2026101310433192200_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"2026101310433192200_bib6","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026101310433192200_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026101310433192200_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.2019002180","article-title":"FLT3 inhibitors added to induction therapy induce deeper remissions","volume":"135","author":"Levis","year":"2020","journal-title":"Blood"},{"issue":"10388","key":"2026101310433192200_bib9","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"2026101310433192200_bib10","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00277-018-3419-1","article-title":"Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"97","author":"Konuma","year":"2018","journal-title":"Ann Hematol"},{"issue":"12","key":"2026101310433192200_bib11","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1007\/s00277-020-04261-6","article-title":"Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT","volume":"99","author":"Yamasaki","year":"2020","journal-title":"Ann Hematol"},{"issue":"9","key":"2026101310433192200_bib12","first-page":"774.e1","article-title":"Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients","volume":"27","author":"Cho","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026101310433192200_bib13","first-page":"683.e1","article-title":"Clinical outcomes and treatment patterns in adults with FLT3-ITD(mut+) acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the United States and Canada","volume":"30","author":"Pandya","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026101310433192200_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026101310433192200_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/bloodadvances.2025016444","article-title":"FLT3-ITD measurable residual disease from the QuANTUM-First trial","volume":"10","author":"Levis","year":"2026","journal-title":"Blood Adv"},{"issue":"12","key":"2026101310433192200_bib16","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/bloodadvances.2025017738","article-title":"Quizartinib in newly diagnosed patients with FLT3-ITD\u2013positive AML who received maintenance therapy in QuANTUM-First","volume":"10","author":"Levis","year":"2026","journal-title":"Blood Adv"},{"issue":"20","key":"2026101310433192200_bib17","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","article-title":"Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Levis","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6754\/2593652\/blooda_adv-2026-020327-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6754\/2593652\/blooda_adv-2026-020327-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:40Z","timestamp":1791902620000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6754\/569986\/Regional-practice-differences-significantly-affect"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":17,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020327","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,10,1]]}}}